Reduction of Myocardial Infarct Size with Ischemic "Conditioning": Physiologic and Technical Considerations

被引:59
|
作者
Przyklenk, Karin [1 ,2 ,3 ]
机构
[1] Wayne State Univ, Sch Med, Cardiovasc Res Inst, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI 48201 USA
关键词
INJURY SALVAGE KINASE; BYPASS GRAFT-SURGERY; REPERFUSION INJURY; POSTCONDITIONING PROTECTS; STUTTERING REPERFUSION; UNDERLYING MECHANISMS; CORONARY THROMBOLYSIS; CONSCIOUS RABBITS; CURRENT KNOWLEDGE; NITRIC-OXIDE;
D O I
10.1213/ANE.0b013e318294fc63
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
A wealth of evidence has revealed that the heart can be "conditioned" and rendered less vulnerable to ischemia-reperfusion injury via the upregulation of endogenous protective signaling pathways. Three distinct conditioning strategies have been identified: (1) preconditioning, the phenomenon where brief episodes of myocardial ischemia (too brief to cause cardiomyocyte death) limit necrosis caused by a subsequent sustained ischemic insult; (2) postconditioning, the concept that relief of myocardial ischemia in a staged or stuttered manner attenuates lethal ischemia-reperfusion injury; and (3) remote conditioning, or upregulation of a cardioprotective phenotype initiated by ischemia in a remote organ or tissue and "transported" to the heart. Progress has been made in defining the technical requirements and limitations of each of the 3 ischemic conditioning models (including the timing and severity of the protective stimulus), as well as elucidating the molecular mechanisms (in particular, the receptor-mediated signaling pathways) responsible for conditioning-induced myocardial protection. Moreover, phase III clinical trials are in progress, seeking to capitalize on the protection that can be achieved by postconditioning and remote conditioning, and applying these strategies in patients undergoing cardiac surgery or angioplasty for the treatment of acute myocardial infarction. There is, however, a potentially important caveat to the clinical translation of myocardial conditioning: emerging data suggest that the efficacy of ischemic conditioning is compromised in aging, diabetic, and hypertensive cohorts, the specific populations in which myocardial protection is most relevant. Successful clinical application of myocardial conditioning will therefore require an understanding of the potential confounding consequences of these comorbidities on the "conditioned" phenotype.
引用
收藏
页码:891 / 901
页数:11
相关论文
共 50 条
  • [41] Various models of cardiac conditioning in single or sequential periods of ischemia: Comparative effects on infarct size and intracellular signaling
    Iliodromitis, Konstantinos
    Farmakis, Dimitrios
    Andreadou, Ioanna
    Zoga, Anastasia
    Bibli, Sofia-Iris
    Manolaki, Theodora
    Dagres, Nikolaos
    Iliodromitis, Efstathios K.
    Anastasiou-Nana, Maria
    Kremastinos, Dimitrios Th.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (02) : 1336 - 1341
  • [42] Remote Limb Ischemic Conditioning during Cerebral Ischemia Reduces Infarct Size through Enhanced Collateral Circulation in Murine Focal Cerebral Ischemia
    Kitagawa, Kazuo
    Saitoh, Moeko
    Ishizuka, Kentaro
    Shimizu, Satoru
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2018, 27 (04) : 831 - 838
  • [43] Reduction of Infarct Size by Short-Term Pretreatment with Atorvastatin
    Yochai Birnbaum
    Taras Ashitkov
    Barry F. Uretsky
    Scott Ballinger
    Massoud Motamedi
    Cardiovascular Drugs and Therapy, 2003, 17 : 25 - 30
  • [44] Myocardial Infarct Size Reduction Provided by Local and Remote Ischaemic Preconditioning: References Values from the Hatter Cardiovascular Institute
    Rossello, Xavier
    He, Zhenhe
    Yellon, Derek M.
    CARDIOVASCULAR DRUGS AND THERAPY, 2018, 32 (02) : 127 - 133
  • [45] Reduction of infarct size by short-term pretreatment with atorvastatin
    Birnbaum, Y
    Ashitkov, T
    Uretsky, BF
    Ballinger, S
    Motamedi, M
    CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (01) : 25 - 30
  • [46] Impact of ischemia and reperfusion times on myocardial infarct size in mice in vivo
    Redel, Andreas
    Jazbutyte, Virginija
    Smul, Thorsten M.
    Lange, Markus
    Eckle, Tobias
    Eltzschig, Holger
    Roewer, Norbert
    Kehl, Franz
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2008, 233 (01) : 84 - 93
  • [47] ACADESINE REDUCES MYOCARDIAL INFARCT SIZE BY AN ADENOSINE-MEDIATED MECHANISM
    ZHAO, ZQ
    WILLIAMS, MW
    SATO, H
    HUDSPETH, DA
    MCGEE, DS
    VINTENJOHANSEN, J
    VANWYLEN, DGL
    CARDIOVASCULAR RESEARCH, 1995, 29 (04) : 495 - 505
  • [48] LIMITATION OF MYOCARDIAL INFARCT SIZE BY NICORANDIL AFTER SUSTAINED ISCHEMIA IN PIGS
    GALIE, N
    GUARNIERI, C
    USSIA, GP
    ZIMARINO, M
    TRAINI, AM
    PARLANGELI, R
    VAONA, I
    BRANZI, A
    MAGNANI, B
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 (03) : 477 - 484
  • [49] Post-conditioning with cyclosporine A fails to reduce the infarct size in an in vivo porcine model
    Lie, R. H.
    Stoettrup, N.
    Sloth, E.
    Hasenkam, J. M.
    Kroyer, R.
    Nielsen, T. T.
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2010, 54 (07) : 804 - 813
  • [50] Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat
    Yochai Birnbaum
    Regina Ye
    Yumei Ye
    Cardiovascular Drugs and Therapy, 2023, 37 : 221 - 224